Cargando…

Lack of utility of phosphate serum monitoring in HIV-infected patients on a tenofovir-based antiretroviral regimen

Detalles Bibliográficos
Autores principales:	Wikman, P, Safont, P, Perez-Elías, MJ, Moreno, A, Dronda, F, Moreno, S, Casado, JL
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112928/ http://dx.doi.org/10.1186/1758-2652-13-S4-P150

Ejemplares similares

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
por: Chua, Arlene C, et al.
Publicado: (2012)

Delayed onset renal failure in a patient on tenofovir based antiretroviral regimen
por: Krishna, M. Murali, et al.
Publicado: (2014)

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
por: Wang, Huilian, et al.
Publicado: (2016)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
por: Manosuthi, Weerawat, et al.
Publicado: (2010)

1014. Factors Associated with Switching from Tenofovir Diproxil Phosphate to a Tenofovir Alafenamide Based Regimen in a Cohort with Unrestricted Access to Care and Medications
por: Ganesan, Anuradha, et al.
Publicado: (2020)

Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho
por: Bygrave, Helen, et al.
Publicado: (2011)

Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen
por: Aurpibul, Linda, et al.
Publicado: (2019)

107. Impact of Switching to an Antiretroviral Regimen Containing Tenofovir Alafenamide on Weight Gain and Development of Metabolic Side Effects
por: Darnell, Julia, et al.
Publicado: (2020)

Adherence to antiretroviral treatment regimens and correlation with risk of hospitalization among commercially insured HIV patients in the US
por: Sax, PE, et al.
Publicado: (2010)

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020)

Lack of a Clinically Meaningful Drug Interaction Between the HIV‐1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate
por: Rudd, Deanne Jackson, et al.
Publicado: (2021)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study
por: Keene, Claire M, et al.
Publicado: (2021)

Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021)

Kidney tubular function and serum phosphate levels in HIV-1-infected patients treated with tenofovir: preliminary results
por: Grima, P, et al.
Publicado: (2010)

Increased Risk of Serious Non-AIDS-Related Events in HIV-Infected Subjects on Antiretroviral Therapy Associated with a Low CD4/CD8 Ratio
por: Serrano-Villar, Sergio, et al.
Publicado: (2014)

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
por: Lazzarin, A, et al.
Publicado: (2010)

Prevalence and factors associated with renal dysfunction in patients on tenofovir disoproxil fumarate-based antiretroviral regimens for HIV infection in Southern India
por: Kumarasamy, Nagalingeswaran, et al.
Publicado: (2018)

Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide
por: Hung, Anna, et al.
Publicado: (2020)

Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar
por: Kyaw, Nang Thu Thu, et al.
Publicado: (2015)

Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States
por: Emond, Bruno, et al.
Publicado: (2022)

Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen
por: Darnell, Julia, et al.
Publicado: (2021)

Drug Synergy of Tenofovir and Nanoparticle-Based Antiretrovirals for HIV Prophylaxis
por: Chaowanachan, Thanyanan, et al.
Publicado: (2013)

Tenofovir substitution in Namibia based on an analysis of the antiretroviral dispensing database
por: Kalemeera, Francis, et al.
Publicado: (2015)

Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring
por: von Wyl, Viktor, et al.
Publicado: (2012)

Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis
por: Nachega, Jean B., et al.
Publicado: (2017)

Determinants of Risk Factors for Renal Impairment among HIV-Infected Patients Treated with Tenofovir Disoproxil Fumarate-Based Antiretroviral Regimen in Southern Vietnam
por: Hoang, Cuong Q, et al.
Publicado: (2020)

Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya
por: Karoney, Mercy Jelagat, et al.
Publicado: (2022)

Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected
por: Gutiérrez, Carolina, et al.
Publicado: (2011)

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy
por: Gianotti, Nicola, et al.
Publicado: (2015)

Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial
por: Thurman, Andrea R., et al.
Publicado: (2021)

Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV
por: Plum, Pierre-Emmanuel, et al.
Publicado: (2021)

Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV
por: McLaughlin, Milena M, et al.
Publicado: (2018)

Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
por: Vizcarra, Pilar, et al.
Publicado: (2020)

Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy
por: Bañón, Sara, et al.
Publicado: (2014)

Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy
por: Horizon, Arash A, et al.
Publicado: (2011)

Antiretroviral regimen complexity as a predictor of adherence
por: Boyle, C, et al.
Publicado: (2010)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens
por: Busca, C, et al.
Publicado: (2022)

Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir
por: Yilma, Daniel, et al.
Publicado: (2020)

Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate
por: Simpson, Solange M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2km8nvaj3njc08i6pc254og1hv